Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New shot could zap skin cancer without surgery

NCT ID NCT07670858

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This early-phase trial tests an injected drug called FLD-103 for nodular basal cell carcinoma, a common skin cancer. About 48 adults will receive either one or several injections directly into their tumor. The main goal is to check safety and find the right dose, while also seeing if the injection shrinks the cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FLD-103 (injected into the tumor)
What this could lead to
If it works, this could lead to a new way to treat basal cell skin cancer without surgery.
What could go wrong
This is a very early, small trial (48 people) testing safety first. It may not shrink tumors or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 48 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * You are between 18 and 85 years old. * You are willing to attend all study visits and follow the study procedures. * You have been diagnosed with at least one nodular basal cell carcinoma (a type of skin cancer) that has never been treated and suitable for treatment and final excision by the Investigator. * You are willing to avoid certain medications during the study as instructed by the study doctor. * You are not currently participating in another clinical study. * If you are a woman who could become pregnant, you must: * Have a negative pregnancy test at the start of the study. * Use effective birth control during the study and for 90 days after your last dose. * Not breastfeed during the study and for 90 days after your last dose. * If you are a man, you must use a condom during the study and for 90 days after your last dose if you have sex with a partner who could become pregnant. Exclusion Criteria: * You are currently breastfeeding. * You have a known allergy or sensitivity to any ingredient in the study drug or to red tattoo ink. * Your skin lesion is located in a high-risk area, such as near the eyes, nose, ears, lips, scalp, or on the hands or fingers. * Your skin lesion needs to be removed urgently. * Your basal cell carcinoma has spread to other parts of the body. * You have received radiation therapy directly on or near the skin lesion being treated in this study. * You have received phototherapy (such as Ultraviolet A or B light therapy) in the past 4 weeks or are expected to receive it during the study. * You have been diagnosed with a liver or kidney disease that the study doctor considers significant. * You are immunocompromised or have an active infection such as Human Immunodeficiency Virus (HIV), Hepatitis B, Hepatitis C or active Tuberculosis. * You have or had another cancer in the past 5 years * You have a skin condition associated with an increased risk of developing skin cancers (such as Xeroderma Pigmentosum). * You have uncontrolled high blood pressure or a heart rhythm problem. * You have had significant alcohol or drug use issues in the past 6 months, or have a mental health condition that the study doctor believes may affect your ability to participate safely. * You are currently taking certain medications that are not allowed during the study * You are an employee or family member of an employee at the study site or of the study doctor.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nodular basal cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    9 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Equity Medical

    RECRUITING

    Bowling Green, Kentucky, 42104, United States

  • Equity Medical

    NOT_YET_RECRUITING

    New York, New York, 10023, United States

  • FNQH Cairns Skin Cancer Clinic

    RECRUITING

    Westcourt, Queensland, 4870, Australia

  • Innovate Clinical Research

    RECRUITING

    Waitara, New South Wales, 2077, Australia

  • Novatrials

    RECRUITING

    Charlestown, New South Wales, 2290, Australia

  • Scientia Clinical Research

    RECRUITING

    Randwick, New South Wales, 2031, Australia

  • Translational Research Institute

    RECRUITING

    Woolloongabba, Queensland, 4102, Australia

  • Veracity Clinical Research

    RECRUITING

    Woolloongabba, Queensland, 4102, Australia

  • Woden Dermatology

    RECRUITING

    Phillip, Australian Capital Territory, 2606, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.